

THE LANCET Microbe

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. *Lancet Microbe* 2022; published online Feb 9. [https://doi.org/10.1016/S2666-5247\(21\)00305-0](https://doi.org/10.1016/S2666-5247(21)00305-0).



A**B**

Figure S1. Anti-Spike RBD IgG levels in individuals with natural SARS-CoV-2 infection.

A) Mean (standard error) anti-Spike RBD IgG titers in individuals post 2 and 4 months on average, after a negative PCR following natural SARS-CoV-2 infection. Individuals have been grouped into three severity categories: requiring oxygen therapy/Intensive Care Unit in the hospital, hospitalized but non-critical disease and mild disease. Note that due to the small number of individuals analyzed, the group requiring oxygen therapy/ICU has been excluded from this panel.

B) Box-and-whisker plots overlaid with individual anti-Spike RBD IgG levels in individuals post 2 and 4 months on average after a negative PCR following natural SARS-CoV-2 infection. Individuals have been grouped into requiring oxygen therapy/Intensive Care Unit in the hospital, hospitalized but non-critical disease and mild disease.